Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Michael Matson
NDM

Michael Matson

Needham
Wall Street Analyst
★★★★★
#297
on 13Foresight · ranked by our own returns
67%
Success Rate
+10.1%
Average Return
67 of 100 calls profitable · -187.4% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 67% of Michael Matson's ratings turned a profit when each position was held for 2 year — averaging +10.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

146 Buy 59 Hold 0 Sell
Michael's Stock Coverage 35 ratings · 2026-11-15
Company Date Position Consensus ⓘ Price Target ⓘ 2-Yr Return vs S&P 500 ⓘ
MMSI
Merit Medical Systems
 Oct 30, 2026 BUY Strong Buy
+15.6% avg upside
16 analysts
$106.00
22.94% Upside
 +2.5% ·
SYK
Stryker
 Oct 30, 2026 BUY Strong Buy
+18.5% avg upside
38 analysts
$359.00
23.09% Upside
 +9.2% ·
RMD
Resmed
 Oct 30, 2026 HOLD Buy
+4.6% avg upside
27 analysts
 — +2.5% ·
NEO
NeoGenomics
 Oct 29, 2026 BUY Strong Buy
+19.1% avg upside
19 analysts
$22.00
26.57% Upside
 -10.7% ·
CNMD
Conmed
 Oct 29, 2026 HOLD Hold
+48.7% avg upside
12 analysts
 — +10.9% ·
BSX
Boston Scientific
 Oct 28, 2026 BUY Strong Buy
+43.0% avg upside
38 analysts
$48.00
14.37% Upside
 +4.5% ·
HAE
Haemonetics
 Oct 21, 2026 HOLD Buy
-20.9% avg upside
18 analysts
 — +4.8% ·
ESTA
Establishment Labs Holdings
 Oct 15, 2026 BUY Strong Buy
+45.5% avg upside
13 analysts
$95.00
52.10% Upside
 +15.3% ·
ENOV
Enovis
 Oct 12, 2026 BUY Strong Buy
+226.7% avg upside
39 analysts
$34.00
70.77% Upside
 +51.7% ·
LUCD
Lucid Diagnostics
 Oct 01, 2026 BUY Strong Buy
+1104.3% avg upside
8 analysts
$3.00
641.06% Upside
 -34.4% ·
INGN
Inogen
 Oct 01, 2026 BUY Hold
+259.6% avg upside
7 analysts
$12.00
74.85% Upside
 -4.9% ·
TMDX
TransMedics Group
 Sep 22, 2026 BUY Strong Buy
+44.6% avg upside
15 analysts
$106.00
60.62% Upside
 +3.8% ·
MDT
Medtronic
 Sep 17, 2026 BUY Buy
+4.4% avg upside
38 analysts
$114.00
18.10% Upside
 +10.0% ·
VCYT
Veracyte
 Sep 15, 2026 BUY Strong Buy
+4.5% avg upside
19 analysts
$69.00
38.06% Upside
 -39.4% ·
ATRC
Atricure
 Sep 02, 2026 BUY Strong Buy
-13.7% avg upside
15 analysts
$64.00
4.46% Upside
 +6.7% ·
TFX
Teleflex
 Aug 25, 2026 BUY Buy
+31.3% avg upside
20 analysts
$170.00
21.57% Upside
 +10.4% ·
IMDX
Insight Molecular Diagnostics
 Aug 18, 2026 BUY Buy
+79.9% avg upside
10 analysts
$9.00
204.10% Upside
 -41.8% ·
PLSE
Pulse Biosciences
 Aug 17, 2026 BUY Strong Buy
+19.3% avg upside
8 analysts
$58.00
10.93% Upside
 +10.7% ·
ICUI
ICU Medical
 Aug 07, 2026 BUY Strong Buy
+6.6% avg upside
9 analysts
$187.00
14.23% Upside
 -3.3% ·
AORT
Artivion
 Aug 07, 2026 BUY Strong Buy
+75.4% avg upside
9 analysts
$44.00
94.83% Upside
 -29.6% ·
STE
Steris
 Aug 06, 2026 HOLD Strong Buy
+5.6% avg upside
10 analysts
 — +9.7% ·
PSNL
Personalis
 Aug 06, 2026 HOLD Buy
-6.1% avg upside
11 analysts
 — +20.6% ·
ZBH
Zimmer Biomet Holdings
 Aug 05, 2026 HOLD Buy
+20.5% avg upside
39 analysts
 — +5.4% ·
INMD
InMode
 Aug 05, 2026 HOLD Buy
+46.1% avg upside
9 analysts
 — -13.7% ·
KIDS
OrthoPediatrics
 Aug 05, 2026 BUY Strong Buy
+9.5% avg upside
10 analysts
$35.00
13.30% Upside
 +45.0% ·
LIVN
LivaNova
 Aug 05, 2026 BUY Strong Buy
+1.1% avg upside
15 analysts
$93.00
17.69% Upside
 +16.8% ·
PEN
Penumbra
 Feb 25, 2026 HOLD Buy
+3.6% avg upside
23 analysts
 — -5.2% ·
TSE:SWA
Sarama Resources
 Apr 05, 2024 HOLD Hold
1 analyst
 — +166.7% ·
GMED
Globus Medical
 May 05, 2021 BUY Strong Buy
+18.8% avg upside
24 analysts
$82.00
5.01% Upside
 -20.3% ·
SIBN
SI-Bone
 Mar 18, 2020 BUY Strong Buy
+22.7% avg upside
18 analysts
$27.00
27.23% Upside
 +140.9% ·
MDXG
MiMedx Group
 Dec 06, 2018 HOLD Strong Buy
+168.0% avg upside
17 analysts
 — +415.8% ·
SINT
Sintx Technologies
 Nov 11, 2016 BUY Strong Buy
+383.1% avg upside
8 analysts
 — · ·
ADMA
ADMA Biologics
 Nov 06, 2015 BUY Strong Buy
-3.8% avg upside
15 analysts
$1.00
91.33% Downside
 -76.8% ·
ISRG
Intuitive Surgical
 Apr 19, 2013 BUY Strong Buy
+12.0% avg upside
37 analysts
$636.00
47.21% Upside
 +11.6% ·
OFIX
Orthofix Medical
 Apr 17, 2009 SELL Strong Buy
+203.8% avg upside
15 analysts
 — -88.5% ·
🔒 30 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Michael Matson — Frequently Asked Questions
How accurate are Michael Matson's stock ratings?
Based on the calls 13Foresight could measure, about 67% of Michael's ratings were profitable over a one-year hold, with an average return of +12.4% per rating, or -183.5% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Michael ranked on 13Foresight?
Michael Matson is currently ranked #297 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Michael cover?
Michael most recently has ratings on MMSI, SYK, RMD, NEO, CNMD, BSX, HAE, ESTA, ENOV, LUCD, INGN, TMDX and 23 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.